8-K: Akoya Biosciences Reports Strong Second Quarter Revenue Rebound and Cost Reductions

Akoya Biosciences announced a 26% sequential revenue increase in Q2 2024, alongside significant reductions in operating expenses and a narrowed loss from operations.

Summary

• Akoya Biosciences reported a revenue of $23.2 million for the second quarter of 2024, marking a 26.2% increase compared to the previous quarter.
• However, this revenue is a 1.5% decrease compared to the same quarter in 2023.
• The company's gross margin improved to 57.8% in Q2 2024, up from 45.7% in Q1 2024 and 51.5% in Q2 2023.
• Operating expenses decreased by 18.3% quarter-over-quarter and 22% year-over-year, reaching $24.5 million in Q2 2024.
• The loss from operations was reduced to $11.1 million in Q2 2024, a 48.6% improvement from Q1 2024 and a 42.4% improvement from Q2 2023.
• Akoya's installed base of instruments grew to 1,264, an 18.8% increase year-over-year.
• The company's technology was cited in 1,450 publications, a 46.8% increase year-over-year.
• Akoya ended the quarter with $48.7 million in cash, cash equivalents, and marketable securities.
• Year-to-date revenue for 2024 is $41.5 million, a 7.6% decrease compared to the same period in 2023.
• The company has updated its full-year 2024 revenue outlook to a range of $96-104 million.

Sentiment

Score: 7

Explanation: The document shows a positive trend with strong revenue rebound and cost reductions, but the company is still operating at a loss and has a year-over-year revenue decrease. The updated revenue outlook is a range, indicating some uncertainty.

Positives

• The company achieved a significant 26.2% sequential revenue growth in Q2 2024.
• Instrument revenue saw a substantial 70.4% increase quarter-over-quarter.
• Gross margin improved significantly to 57.8% in Q2 2024.
• Operating expenses were reduced by 18.3% quarter-over-quarter and 22% year-over-year.
• The loss from operations decreased by 48.6% quarter-over-quarter and 42.4% year-over-year.
• The installed base of instruments grew by 18.8% year-over-year.
• The number of publications citing Akoya's technology increased by 46.8% year-over-year.

Negatives

• Q2 2024 revenue decreased by 1.5% compared to Q2 2023.
• Year-to-date revenue for 2024 is down 7.6% compared to the same period in 2023.
• The company reported a loss from operations of $11.1 million for Q2 2024.
• The company has a net loss of $13.149 million for the quarter.

Risks

• The company's revenue is still down year-over-year despite the sequential growth.
• Akoya is still operating at a loss, although the loss is decreasing.
• The company's ability to achieve operating cash flow breakeven by year-end is not guaranteed.
• The company's updated revenue outlook for 2024 is a range, indicating some uncertainty.

Future Outlook

Akoya is updating its revenue outlook for the full year 2024 to be in the range of $96-104 million, while maintaining its commitment to achieving operating cash flow breakeven by year end.

Management Comments

• Brian McKelligon, CEO of Akoya Biosciences, stated that the second-quarter revenue showed a strong rebound with 26% sequential top-line growth.
• He also believes that Akoya's platforms are poised to lead the spatial biology market from discovery to diagnostics.
• The CEO also mentioned the company is positioning itself to achieve near-term operating cash flow breakeven as they align their cost structure with their strategic objectives.

Industry Context

The announcement reflects a positive trend in the spatial biology market, with Akoya showing strong growth in instrument sales and publications, indicating increasing adoption of their technology. This is in line with the broader trend of increased interest and investment in advanced biological research tools.

Comparison to Industry Standards

• Akoya's 26% sequential revenue growth in Q2 is a positive sign, indicating a strong rebound from Q1. This is a significant improvement compared to companies like NanoString Technologies, which have faced challenges in recent quarters.
• The 70.4% quarter-over-quarter increase in instrument revenue is particularly noteworthy, suggesting strong demand for their PhenoCycler and PhenoImager platforms. This is a key differentiator compared to companies that rely more heavily on consumables.
• The improvement in gross margin to 57.8% is a positive development, indicating better cost management and pricing power. This is comparable to other life science companies with established product lines.
• The reduction in operating expenses by 18.3% quarter-over-quarter and 22% year-over-year demonstrates the company's focus on efficiency and cost control. This is a critical factor for achieving profitability, which is a common challenge for growth-stage companies in the biotech sector.
• The 46.8% year-over-year increase in publications citing Akoya's technology is a strong indicator of the scientific community's acceptance and validation of their platform. This is a key metric for companies in the life sciences industry, as it demonstrates the impact and utility of their products.

Management Changes

Stakeholder Impact

• Shareholders will likely view the strong revenue rebound and cost reductions positively.
• Employees may be impacted by the restructuring and cost-cutting measures.
• Customers will benefit from the continued development and improvement of Akoya's spatial biology solutions.
• Suppliers may be affected by changes in the company's operations and cost structure.
• Creditors will be interested in the company's progress towards achieving operating cash flow breakeven.

Next Steps

• Akoya will continue to focus on achieving operating cash flow breakeven by year-end.
• The company will continue to execute its strategic objectives to lead the spatial biology market.

Key Dates

Keywords

Spatial Biology, Akoya Biosciences, Financial Results, Revenue, Gross Margin, Operating Expenses, Loss from Operations, Instruments, PhenoCycler, PhenoImager, Publications